Phio Pharmaceuticals Corp.
PHIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $135,621 | $11,268 | $0 | $14,174 |
| - Cash | $10,705 | $10,775 | $13,278 | $5,382 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $124,916 | $493 | -$13,278 | $8,792 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$2 | -$1,074 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$2,390 | -$2,309 | -$1,769 | -$1,626 |
| % Margin | – | – | – | – |
| Net Income | -$2,392 | -$2,166 | -$1,769 | -$1,626 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.44 | -0.45 | -41,070.15 | -0.37 |
| % Growth | 2.2% | 100% | -11,099,940.5% | – |
| Operating Cash Flow | -$2,085 | -$2,540 | -$1,275 | -$1,371 |
| Capital Expenditures | -$7 | -$3 | -$2 | -$1 |
| Free Cash Flow | -$2,092 | -$2,543 | -$1,277 | -$1,372 |